Catalyst Pharmaceuticals appoints Richard J. Daly as CEO, effective Jan 1, 2024

CATALYST PHARMACEUTICALS, INC.

Patrick J. McEnany retires as CEO effective Dec 31, 2023, remains Chairman of the Board.
Richard J. Daly, Board member since 2015, named CEO; previously President at CARsgen, CEO of Neuralstem.
Daly receives base salary of $750,000, bonus up to 75% of base, stock options for 1,365,319 shares at $13.30.
Options and restricted stock units vest in 5 annual installments starting Jan 1, 2025.
Daly to become consultant from Dec 1, 2023 for transition with McEnany.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Patrick J. McEnany

Chairman of the Board

CPRX · CATALYST PHARMACEUTICALS, INC.

Effective: 2023-12-31
Successor: Richard J. Daly
Filed: October 20, 2023, 7:59 PM ET

The Company’s current CEO, Patrick J. McEnany, will continue to serve as the Company’s CEO until December 31, 2023 and, following his retirement as the Company’s CEO, will continue to serve on the Company’s Board of Directors (“ Board ”) as the non-executive Chairman of the Board.

Appointed

Richard J. Daly

Chief Executive Officer

CPRX · CATALYST PHARMACEUTICALS, INC.

Effective: 2024-01-01
Filed: October 20, 2023, 7:59 PM ET

the appointment of Richard J. Daly, 62, as its Chief Executive Officer (“ CEO ”), to become effective on January 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick J. McEnany retired as Chairman of the Board at CATALYST PHARMACEUTICALS, INC..

Action: retired
Role: Chairman of the Board

Exact text from the filing

The Company’s current CEO, Patrick J. McEnany, will continue to serve as the Company’s CEO until December 31, 2023 and, following his retirement as the Company’s CEO, will continue to serve on the Company’s Board of Directors (“ Board ”) as the non-executive Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard J. Daly was appointed as Chief Executive Officer at CATALYST PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the appointment of Richard J. Daly, 62, as its Chief Executive Officer (“ CEO ”), to become effective on January 1, 2024.

View on SEC.gov

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-259961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.